Refractory Active Systemic Lupus Erythematosus

1

Review clinical trials related to Refractory Active Systemic Lupus Erythematosus. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus

This study aimed to observe the safety and tolerability of SYS6020 in adult participants with refractory active systemic lupus erythematosus, determine the recommended dose (RD) that may be explored for subsequent studies, and preliminly evaluate the clinical efficacy of this product,and explore the pharmacokinetics and immunogenicity of SYS6020 injection in those participants.

Participants needed: 50
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Updated: Nov 19, 2024
Eligibility criteria

1. Age ≥18 years old, ≤70 years old; [+6]

1. Severe lupus nephritis within 8 weeks before screening; [+10]